Softox Solutions As · OSL:SOFTX
Softox Solutions As — Q3 2022 Earnings Presentation
34 slides from Softox Solutions As's earnings presentation, Oct 26, 2022
Slide 1: SoftOx Solutions AS Presentation Q3 2022
SoftOx Solutions AS Medtech and pharmaceutical company listed on Euronext Growth Presentation Q3 2022 26 October 2022
Slide 2: Disclaimer
Disclaimer This Presentation has been produced by SoftOx Solutions AS (the “Company” or “SoftOx”), solely for use at the presentation to investors held in connection with Q3 2022. This presentation is strictly confidential and may not be reproduced or redistributed, in whole or in part, to any other
Slide 3: Presenters
Presenters Highlights, SoftOx in brief & Commercial development CEO Geir Almås SoftOx technology development CMO Dr Christopher Burton Financial review CFO Kristine Rød 3 | 3rd quarter results 2022
Slide 4: Third quarter highlights and SoftOx in brief
Third quarter highlights and SoftOx in brief
Slide 5: Helping the world fighting infections
Helping the world fighting infections VIRUSES BIOFILM RESISTANCE ANTIMICROBIAL RESISTANCE Respiratory infectious diseases are 1-2% of the population are projected AMR is regarded as one of the among the leading causes of death [1 to experience a chronic wound during biggest threats to global health
Slide 6: Third quarter highlights and subsequent events
Third quarter highlights and subsequent events RESEARCH & DEVELOPMENT Early completion of SBE-01 study evaluating the SoftOx Biofilm Eradicator (SBE) in treating chronic wounds Positive top line results of SBE-01 showed SBE was safe and well tolerated Selected as one of three main technologies that
Slide 7: Product pipeline – Good progress in clinical development programs
Product pipeline – Good progress in clinical development programs Phase II/ Product Pre-clinical/ Phase I/ Confirmative Pending regulatory classification Project Indication EN studies Pilot studies studies approval Disinfection Surface disinfectant BIOCIDE (SafeDes & EffectDes) Hand disinfectant Kem
Slide 8: SoftOx technology development
SoftOx technology development
Slide 9: SoftOx technology – stable and long-lasting product with unique combination effects
SoftOx technology – successfully developed a stable and long-lasting product with unique combination effects 1. SOFTOX TECHNOLOGY 2. Strong pan-spectrum antimicrobial HYPOCHLOROUS ORGANIC (virucidal/bactericidal) effects ACID ACID Documented broad Antimicrobial 3. Not shown to induce antimicrobial r
Slide 10: Business segments
Business segments Wounds Respiratory Disinfection Infection prevention and Treatment of viral Infection prevention treatment for acute and infections solutions for hands and chronic wounds surfaces 10 | 3rd quarter results 2022 SoftOx in brief SoftOx technology Markets/ Commercial development Financ
Slide 11: Infection is one of the most frequent factors associated with delayed wound healing
Infection is one of the most frequent factors associated with Wound delayed wound healing1 VLU Bacteriology 2 Percentage of wounds colonised (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Representative CLSM images of S. aureus (A and B), P. aeruginosa (C and D). Arrows point to the wound surfaces.
Slide 12: First line prevention and treatment of locally infected wounds
First line prevention and treatment of locally infected wounds Wound (i.e. no evidence of systemic infection) TREATMENT PREVENTION Figure. The typical evolution of a superficial wound infection. By definition, VLUs are most likely A Proposed New Classification of Skin and Soft Tissue Infections Mode
Slide 13: Positive results from Phase 1 in treatment of chronic wounds (SBE-01)
Positive results from Phase 1 in treatment of chronic wounds Wound (SBE-01) investigating single- and multiple ascending doses SBE Single dose 500 ppm HOCl, 1% HAc Topline results Single dose 500 ppm HOCl, 2% HAc - Safe and well tolerated Single dose - SBE formulations reduced the absolute number 50
Slide 14: Positive results from Phase 1 in chronic wounds: bacterial burden
Positive results from Phase 1 in treatment of chronic wounds Wound (SBE-01) investigating single- and multiple ascending doses SBE 1,E+08 1,E+07 Topline results 1,E+06 - Safe and well tolerated Bacterial burden (CFU/mL) 1,E+05 - SBE formulations reduced the absolute number 1,E+04 of bacteria (bacter
Slide 15: Positive results from Phase 1 in chronic wounds: wound area change
Positive results from Phase 1 in treatment of chronic wounds Wound (SBE-01) investigating single- and multiple ascending doses SBE Relative Change from pre-dose wound area after 5 days treatment* SBE (QD) SBE (BID) Topline results 0% - Safe and well tolerated -10% Relative change in wound area - SBE
Slide 16: Clinical effect of re-epithelialization in acute wounds supports chronic wound findings
Clinical effect of re-epithelialization in acute wounds supports Wound finding in chronic wounds Mean Difference in degree of re-epithelialization: Picture of re-epithelialization in acute wounds: SWIS vs. sterile saline SWIS vs. sterile saline 35% Degree of Re-epithelialization (%) 30% 25% Mean Dif
Slide 17: SBE-02 - US Phase 2 follow up study
SBE-02 - US Phase 2 follow up study Wound • Blinded, randomised, PC, 2 arm: SBE vs. Normal Sterile Saline (NSS) • Patients with chronic ulcers of lower extremities (VLU) • Treatment regimen: Once daily, 3 times per week for 4 weeks • End points: • Clinical evaluation of wound • Microbial determinati
Slide 18: Business segments
Business segments Wounds Respiratory Disinfection Infection prevention and Treatment of viral Infection prevention treatment for acute and infections solutions for hands and chronic wounds surfaces 18 | 3rd quarter results 2022 SoftOx in brief SoftOx technology Markets/ Commercial development Financ
Slide 19: SoftOx Inhaled Solution (SIS): Summary of development within civilian indication
SoftOx Inhaled Solution (SIS): Summary of development Respiratory within civilian indication Civilian treatment Non-clinical Clinical safety Clinical proof of Confirmatory of endemic proof of disease and tolerability concept clinical studies concept 19 | 3rd quarter results 2022 SoftOx in brief Soft
Slide 20: SIS: Exploring potential military applications as a countermeasure to biologic threats
SoftOx Inhaled Solution (SIS): Exploring potential military Respiratory applications as a countermeasure to biologic threats Civilian treatment Non-clinical Clinical safety Clinical proof of Confirmatory of endemic proof of disease and tolerability concept clinical studies concept SIS non-clinical i
Slide 21: SIS: Exploring potential military applications as a countermeasure to biologic threats
SoftOx Inhaled Solution (SIS): Exploring potential military Respiratory applications as a countermeasure to biologic threats Civilian treatment Non-clinical Clinical safety Clinical proof Confirmatory of endemic proof of disease and tolerability of concept clinical studies concept SIS clinical safet
Slide 22: SIS: Exploring potential military applications as a countermeasure to biologic threats
SoftOx Inhaled Solution (SIS): Exploring potential military Respiratory applications as a countermeasure to biologic threats Civilian treatment Non-clinical Clinical safety Clinical proof of Confirmatory of endemic proof of disease and tolerability concept clinical studies concept Bridging Bridging
Slide 23: Business segments
Business segments Wounds Respiratory Disinfection Infection prevention and Treatment of viral Infection prevention treatment for acute and infections solutions for hands and chronic wounds surfaces 23 | 3rd quarter results 2022 SoftOx in brief SoftOx technology Markets/ Commercial development Financ
Slide 24: Regulatory approval in Sweden
Regulatory approval in Sweden Disinfection Swedish Chemicals Agency final approval – October 2022 • Received final approval on application for SoftOx biocidal product family for hand and surface disinfection • Approval allows SoftOx to sell its disinfection products in Sweden • Can be used as basis
Slide 25: Markets & commercial development
Markets & commercial development
Slide 26: Market potential in disinfection
Market potential in disinfection Disinfection Cost-saving and life-improving Clinically proven skin friendliness “The skin barrier function of the healthy skin is 75% 25-55% unaffected by the repetitive exposure to SafeDes of HCWs with hand eczema have solution as compared to alcohol-based hand rubs
Slide 27: Market potential in wound care
Market potential in wound care Wound ACUTE WOUNDS CHRONIC WOUNDS 180 million 40 million 1-2% of population are projected to have a Individuals have skin wounds worldwide each year[1 Chronic wounds worldwide[1 chronic wound in developed countries[2 Venous leg ulcers (VLUs) Today’s wound rinse market
Slide 28: Market potential of inhalation solutions
Market potential of inhalation solutions Respiratory Defence Civil Expected 3-year stock 250 million units within NATO & 12% experiences flu-like symptoms annually partners2 30% 100% Unmet Need 25% Percentage of patients with 2M soldiers 10 - 20 pcs flu-like symptoms (%) 20% (partner countries) for
Slide 29: Financial review
Financial review
Slide 30: Financial review
Financial review Profit and loss statement Accounts for Q3 and FY 2021 SoftOx Solutions Group NOK 1,000 Q3 2022 Q3 2021 Change FY 2021 Operating revenue Operating revenue 0 -382 1 752 Low operating income due to low sales Grants 2 037 1 895 6 150 Total operating revenues 2 037 1 513 35% 7 901 Person
Slide 31: Financial review
Financial review Cash flow statement Q3 2022 Q3 2021 FY 2021 Net change in cash and cash SoftOx Solutions Group NOK 1,000 equivalents Cash flow from operating activities -2 603 -13 713 -72 561 • Strong focus on the product Net result before taxes -23 720 -22 036 -86 291 development and Depreciation
Slide 32: Summary
Summary
Slide 33: Future SoftOx technology platform opportunities
Future SoftOx technology platform opportunities Respiratory virucidal Platform products under development infections* Hand disinfection Topical infection prevention for non-compromised skin Acute surgical wounds* Wound care for chronic and acute wounds Topical infection prevention Topical infect
Slide 34: Unique solution for eradicating infections and fighting antimicrobial resistance
Unique solution for eradicating infections and fighting antimicrobial resistance Contact Information: ir@soft-ox.com Euronext Growth ticker: SOFTX